Targepeutics
WebTargepeutics is a biopharmaceutical company developing selective molecularly targeted therapeutics to fight cancer and other diseases. Our lead compound, GB-13, is currently … WebTargepeutics announces a Phase I Small Business Innovation Research (SBIR) grant awarded to Dr Randy Schrecengost as Primary Investigator to support preliminary data demonstrating that GB13 can specifically target IL13Rα2-positive pediatric Diffuse Midline Glioma with H3K27 alterations tumor models. Along with Co-investigator Dr David Daniels ...
Targepeutics
Did you know?
WebJan 5, 2007 · Targepeutics is developing increasingly specific and potent IL-13 mutants for targeting cancer. Our optimism regarding GB13 was recently reinforced by the release of … WebJun 21, 2012 · Targepeutics: Inhaled-IL4 Research Project: Recombinant IL-4 antagonist: Cosmix--* Phase II is for idiopathic pulmonary fibrosis indication: The deal with Rigel. R256, the molecule Rigel has licensed to AstraZeneca, has so far only been studied in preclinical models, in which it was shown to prevent allergen-induced airway hyper-responsiveness ...
WebNews for GB-13 / Targepeutics. IL-13Rα2 immunoconjugate targeted therapy for H3K27M-mutant midline gliomas (SNO 2024) - "Furthermore, we observed enhanced drug tissue … WebTargepeutics is a biopharmaceutical company developing selective molecularly targeted therapeutics to fight and diagnose cancer and other diseases. The firm's lead compound, GB-13, is reported as advancing toward a Phase I clinical trial for several cancer targets. GB-13 is a genetically engineered recombinant protein that specifically binds ...
WebJan 21, 2024 · Targepeutics has a streamlined development program for GB13, including multiple viable target cancers and delivery in combination with other agents. Visit … WebTargepeutics patents and patents pending include the use of a mutant form o f Interleukin 13, IL13.E13K, which preferentially binds to cancer specific IL13Ra2 but not to the broadly …
Web1214 Research Blvd., Suite 1011, Hummelstown, PA 17036 (717) 571-2402
Webcancer cells by leveraging IL13/receptor association. As such, Targepeutics has developed a mutated IL13-derived toxin, called GB13, that preferentially binds to IL13Rα2 and possesses a Pseudomonas exotoxin moiety to kill targeted cells.The three aims of this project independently work to develop the clinical advancement of GB13 for the caged shelvesWebTargepeutics has now obtained orphan drug designation for GB-13 from the Food and Drug Administration (FDA), opening paths to needed resources. GB-13 specifically targets a … The majority of current cancer therapies kill tumor cells but also kill normal cells, … Over 70% of adult glioblastomas (GBM) and pediatric diffuse midline glioma (DMG) … Dr Schrecengost brings 20 years of cancer research to the team with more than a … 1214 Research Blvd., Suite 1011, Hummelstown, PA 17036 (717) 571-2402 1214 Research Blvd., Suite 1011, Hummelstown, PA 17036 (717) 571-2402 Contact Get in touch with us to discuss strategic partnerships or to learn more … cmt honorsWebTargepeutics in the US was developing a series of small soluble proteinaceous compounds suitable for delivery by an inhaler as potential therapeutics for Research programme: … cmth-m12-iolx2-h1141WebJun 22, 2010 · LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics (OTCBB: IMUC), a clinical-stage biotechnology company focused on developing new immune-based products to treat cancer, today announced it has entered into an exclusive licensing agreement with Targepeutics, Inc. for ImmunoCellular’s acquisition of Targepeutics’ … caged soccerWebTargepeutics has an intellectual property portfolio including several issued patents and numerous additional patens pending, focused on novel targeted oncology therapeutics and diagnostics. Targepeutics patents and patents pending include the use of a mutant form of Interleukin 13, IL13.E13K, which preferentially binds to cancer specific ... cmt honors randy travisWebTargepeutics in the US was developing a series of small soluble proteinaceous compounds suitable for delivery by an inhaler as potential therapeutics for Research programme: asthma therapeutics - Targepeutics - AdisInsight caged sefipcmt home facebook